http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2761438-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d07a4ddba85ae3e35ca0a6f85dad9f6d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_14ff914f259bb631f31d4b32b1eaddd4
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
filingDate 2010-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba6ef06885ac636260604f52792d7074
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe4b6d806a47c0e5ed025c4f94356178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00fa2f4cd0a7f4594850b7b1051f874b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4133a6ea6ead5139ecff8a541efe05de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8d2fbc62d349e241804f6afe7fe834e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b8a654c697449b7177222fd25a2ccd3
publicationDate 2010-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2761438-A1
titleOfInvention Compositions and methods for treating hematologic cancers targeting the sirp.alpha.-cd47 interaction
abstract The invention relates to modulating the SIRP.alpha.-CD47 interaction in order to treat hematological cancer and compounds therefor. In some embodiments, there is provided methods and uses of SIRP.alpha. polypeptides, fragments and fusion proteins for treating hematological cancer, preferably human acute myeloid leukemia.
priorityDate 2009-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419494003
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458395493
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419564680
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71308181
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID428401458
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID22094277
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25419

Total number of triples: 35.